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A number of small-molecule inhibitors have been
developed that target the catalytic domains of
protein kinases that are not in an active conforma-
tion. An inactive form that has been observed in
several kinases is the DFG-out conformation. This
conformation is characterized by an almost 180
rotation of the conserved Asp-Phe-Gly (DFG) motif
in the ATP-binding cleft relative to the active form.
However, the sequence and structural determinants
that allow a kinase to stably adopt the DFG-out
conformation are not known. Here, we characterize
a series of inhibitors based on a general pharmaco-
phore for this inactive form. We demonstrate that
modified versions of these inhibitors can be used to
study the thermodynamics and kinetics of ligand
binding to DFG-out-adopting kinases and for enrich-
ing these kinases from complex protein mixtures.
INTRODUCTION
Comprised of over 500 members, protein kinases are the largest
enzyme family encoded by the human genome (Manning et al.,
2002). These enzymes are the major mediators of intracellular
protein phosphorylation cascades and are involved in complex
phenotypic responses such as growth, differentiation, adhesion,
and motility (Cohen, 2000). The proper spatial and temporal
control of intracellular phosphorylation events by protein kinases
is essential for normal cellular function. Indeed, aberrant kinase
activity has been implicated in numerous diseases including
cancer, diabetes, and chronic inflammation (Cohen, 2002). For
this reason, there has been considerable effort toward the
development of pharmacological agents that target this
enzyme family.
The overall structure of the catalytic domain of protein kinases
is highly conserved (Figure 1A) (Hanks and Hunter, 1995). It
consists of 250–300 residues that form a bi-lobal structure con-
taining a smaller, mostly b stranded, N-terminal domain and
a larger, mostly a-helical, C-terminal domain (Taylor et al.,
1988). Adenosine 50-triphosphate (ATP) sits in a narrow hydro-
phobic cleft between the N- and C-terminal lobes, with the
purine moiety forming a pair of hydrogen bonds with the hinge
region (Engh and Bossemeyer, 2001). Most protein kinases
possess at least two distinct catalytic states: an active state
where all of the catalytic residues are in an optimal position forChemistry & Biology 17, 195phosphate transfer and an inactive state (or states) with reduced
catalytic activity (Huse and Kuriyan, 2002). The conformation of
the ATP-binding site in these two states can be quite distinct,
characterized by large conformational shifts in several con-
served catalytic residues. A number of phosphorylation events
and protein-protein interactions regulate the conformational
state of these enzymes (Jeffrey et al., 1995; Pellicena and Kur-
iyan, 2006; Wong et al., 2004).
The ATP-binding sites of protein kinases in the active confor-
mation are very similar, while the structures of inactive kinases
are much more varied (Engh and Bossemeyer, 2001; Kornev
et al., 2006). A specific inactive form of the ATP-binding cleft
that has been observed in a number of kinases is the DFG-out
conformation (Liu and Gray, 2006; Okram et al., 2006). Several
potent kinase inhibitors have been found to selectively bind to
the DFG-out conformation of their kinase targets (type II inhibi-
tors). In many cases, these type II inhibitors exhibit a high degree
of selectivity. Despite the selectivity demonstrated by some type
II inhibitors, a set of conserved binding interactions in the ATP-
binding pocket has been observed (Jacobs et al., 2008; Liu
and Gray, 2006; Nagar et al., 2002; Okram et al., 2006; Simard
et al., 2009a). While the DFG-out conformation appears to be
energetically accessible to a number of kinases, the sequence
and structural determinants that allow this transition are still
poorly understood. Furthermore, it is still not possible to predict
which members of the kinome can be effectively targeted with
type II inhibitors. Identifying the full complement of kinases that
are able to stably adopt this inactive conformation will shed light
on the catalytic regulation of protein kinases and may yield new
targets for drug discovery.
Here we report the development of a set of affinity probes that
are derived from a general type II ligand for the DFG-out confor-
mation of protein kinases. We show that fluorophore-conjugated
analogs of these ligands are useful probes for measuring the
thermodynamics and kinetics of type II inhibitor binding to
protein kinases. In addition, we demonstrate that these reagents
are capable of selectively enriching protein kinases that can
adopt this inactive form from complex protein mixtures. Using
these probes we provide evidence that the STE20 kinase LOK
behaves like a kinase that can adopt the DFG-out conformation.
RESULTS
A General Type II Inhibitor Scaffold
In order to develop a set of reagents for investigating inactive
forms of protein kinases we wished to identify a general ligand
for the DFG-out conformation. Recently, we have characterized
a series of triazolopyridines that are equipotent inhibitors of the–206, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 195
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Affinity Reagents for Inactive Protein Kinasestyrosine kinases SRC and ABL (Seeliger et al., 2009). Through
structural and kinetic studies we demonstrated that this class
of inhibitors binds to the DFG-out conformation of these kinases.
The general bindingmodeof the triazolopyridine ligands is similar
to other type II inhibitors that have been described (Figure 1B;
PDB IDs: 3G6G and 3G6H). The aniline and triazine groups (rings
A and B) form a pair of hydrogen bonds with the hinge region and
occupy the hydrophobic cleft used by adenine. Rings C and D
serve as a linker connecting the adenine-binding region to
a hydrophobic pocket (DFG-out pocket) that is created by the
nearly 180 rotation of the Phe in the DFG motif to a more
solvent-exposed position. Upon entering the DFG-out pocket,
the amide group connecting rings D and E forms a pair of
hydrogen bonds with a conserved glutamate in the helix aC
and the backbone of the DFG motif. Finally, ring E occupies the
DFG-out pocket. A small panel of inhibitors based on the triazo-
lopyridine scaffold was generated to determine the generality of
this ligand class (Figure 1C). For inhibitor series 1 and 2, the
substituents that occupy the DFG-out pocket and exit the
adenine-binding site were varied (rings A and E), while the core
scaffold (rings B, C, and D) was held constant. Compounds 1a
and 2a contain a 3-trifluoromethylbenzamide group, which is
a common binding element in many type II inhibitors (Liu and
Gray, 2006; Okram et al., 2006). Compounds 1b and 1c contain
functional groups that are components of selective type II inhib-
itors: 1b contains a 2-morphilinopyridyl group, which is the phar-
macophore that occupies the DFG-out pocket in the selective
type II p38 MAPK inhibitor MPAQ, and compound 1c contains
the functional groups that are present in the selective type II
BCR-ABL inhibitor nilotinib (Cumming et al., 2004; Sullivan
et al., 2005; Weisberg et al., 2005). Finally, compound 2d was
generated as a control compound due to its lack of a substituent
that occupies the DFG-out pocket. In addition to the triazolopyr-
idine inhibitors fromseries 1, a pyrimidinepyridine compound (3a)
was also generated to determine the role of scaffold structure.
To determine whether the inhibitors generated are potent
ligands for kinases that adopt the DFG-out conformation, they
were tested against a panel of kinases in which high resolution
crystal structures of the catalytic domain are available. Crystal
structures of the tyrosine kinases SRC, LCK, ABL, PYK2, CSK,
and c-KIT and the serine/threonine kinase p38a in the DFG-out
conformation have been obtained and these kinases have
been found to be sensitive to type II inhibitors (Han et al., 2009;
Mol et al., 2004; Seeliger et al., 2009; Simard et al., 2009b). In
contrast, the serine/threonine kinases PKA, PAK4, PAK5,
CLK1, MAP3K5, IRAK4, and ERK2 have not been observed in
this inactive form and inhibitor selectivity screens have shown
them to only be sensitive to type I inhibitors (Fedorov et al.,Figure 1. The DFG-Out Conformation of Protein Kinases and Type II In
(A) The catalytic domain of the tyrosine kinase SRC bound to the type II inhibitor 2
mate in helix aC (shown in yellow) and the conserved aspartate and phenylalanin
bound to type II inhibitors. Kinase subpockets occupied by type II inhibitors are
(B) A schematic representation of 2a bound to the tyrosine kinase SRC. This inhi
acteristic set of hydrogen bonds that type II inhibitors form with the conserved glu
DFG motif are shown. The DFG-out pocket that is generated by the movement o
(C) Chemical structures of inhibitors 1a-1c, 2a, 2d, and 3a.
(D) IC50s of the inhibitors shown in (C) against a diverse panel of kinases. Potencie
inhibitors 1a and 2a for SRC, ABL, andHCK (Seeliger et al., 2009). In this publicatio
were run in triplicate or quadruplicate.
Chemistry & Biology 17, 1952007). The results of the inhibition assays are shown in
Figure 1D. SRC, LCK, ABL, PYK2, CSK, HCK, p38, and c-KIT
were potently inhibited by most of the type II inhibitors (1a–1c,
2a, and 3a), while kinases that have not previously been
observed in the DFG-out conformation show little or no inhibition
at the highest concentration tested (1 mM). Consistent with these
inhibitors binding to the DFG-out conformation, control com-
pound 2d shows minimal inhibition of kinases that are sensitive
to type II inhibitors. Surprisingly, the identity of the aryl group
that projects into the DFG-out pocket has only a small impact
on the selectivity profile among DFG-out-adopting kinases.
BODIPY-Labeled Compounds as Binding Probes
for Protein Kinases
In most cases, the potencies of compounds that bind the DFG-
out inactive conformation have been determined by their ability
to inhibit activated kinases. However, this method of analysis
does not allow kinase forms with low catalytic activity to be
probed and it is often difficult to correlate the observed inhibition
to the binding of a specific kinase conformation. A direct binding
assay has the ability to measure ligand affinity for any activa-
tion state of a protein kinase and allows binding kinetics to be
determined. For this reason, we determined the feasibility of con-
verting our general type II inhibitors into fluorescently-labeled
binding probes. Based on a previously reported crystal structure
of inhibitor 2a bound to SRC, the solvent-exposed 4-position of
ring A was selected as the site of fluorophore attachment
(Figure 2A). Because inhibitors 1a and 2a have similar potencies
against most kinases, a BODIPY-FL fluorophore was conjugated
to the monoalkoxy derivative 1a. To determine whether fluoro-
phore attachment significantly affects the potency of this inhib-
itor against protein kinases, in vitro activity assays were per-
formed with p38 and SRC. Gratifyingly, the IC50 of probe 4a for
SRC and p38 is similar to inhibitor 1a (Figure 2B).
We hypothesized that probe 4a would show an increase in
fluorescence when bound to the ATP-binding cleft of a protein
kinase. To test this, 10 nM of probe 4a was incubated with
increasing concentrations of the catalytic domains of ABL or
p38 (1–250 nM). In the presence of these kinases, probe 4a
demonstrated a concentration-dependent increase in fluores-
cence (Figure 2C, top). To confirm that the observed increase
in fluorescence is due to a specific interaction in the ATP-binding
pocket, this experiment was repeated in the presence of an
excess of a competitor that does not contain a fluorophore
(1 mM of 1a). As expected, no increase in fluorescence was
observed for either kinase in the presence of excess competitor
(Figure 2C). Having validated our binding assay with p38 and
ABL, the Kd values of probe 4a for a panel of kinases washibitors
a. The ATP-binding cleft is in the DFG-out conformation. The conserved gluta-
e in the DFG motif (shown in black) are in conformations observed for kinases
indicated by dashed circles.
bitor forms two hydrogen bonds with the hinge region of the kinase. The char-
tamate residue in the helix aC and the amide backbone of the aspartate of the
f the phenylalanine residue of the DFG motif is shaded.
s are represented in grayscale. Note: We have previously reported the IC50s of
n these compounds are referred to asDSA7 andDSA1, respectively. All assays
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Figure 2. Fluorophore-Labeled Ligands for Studying the Kinetics and Thermodynamics of Type II Inhibitor Binding
(A) Crystal structure of 2a bound to the catalytic domain of SRC T338I (PDB ID: 3G6H). DFG motif, magenta; helix aC, teal.
(B) Conversion of compound 1a into a BODIPY-labeled binding probe (4a). IC50 values of 4a against SRC and p38 in activity assays.
(C) (Top) Change in fluorescence observed with increasing concentrations of kinases (ABL, green; p38, purple) in the presence of fluorescent probe 4a (10 nM)
and in the presence of both 4a (10 nM) and competitor 1a (1000 nM). (Bottom) Change in fluorescence observed with increasing concentrations of the kinases
SRC, CSK, LCK, PAK4, CLK1, and MAP3K5 in the presence of 4a (10 nM).
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Table 1. Kd Values of Kinases Determined with 5 nM (ABL, SRC,
and HCK) or 10 nM (LCK, p38, CSK, EPHA3, CLK1, PAK4, PAK5,
and MAP3K5) 4a
Kd (nM)
ABL 9.9 ± 1.6
SRC 13 ± 2
HCK 8.7 ± 0.6
LCK 20 ± 2
p38 35 ± 11
CSK 17 ± 3
EPHA3 27 ± 5
CLK1 >1000
PAK4 >1000
PAK5 >1000
MAP3K5 >1000
Values shown are the average of three assays ± SEM.
Table 2. Kd, t1/2, and koff Values for Imatinib-ResistantMutants of
ABL and the Corresponding SRC Mutants
Mutants Kd (nM) t1/2 (min) koff (s
1)
ABL wt 9.9 ± 1.6 220 ± 3 5.2 3 105
ABL E255V 45 ± 4 234 ± 5 4.9 3 105
ABL Y253H 9.4 ± 1.2 195 ± 7 5.9 3 105
SRC wt 13 ± 2 162 ± 4 7.3 3 105
SRC E280V 15 ± 2 133 ± 18 9.0 3 105
SRC F278H 12 ± 3 167 ± 4 6.9 3 105
SRC T338I 11 ± 1 67 ± 9 1.8 3 104
p38 35 ± 11 72 ± 1 1.6 3 104
Kd values for ABL and SRC were determined with 10 nM 4a. Values
shown are the average of three assays ± SEM.
Chemistry & Biology
Affinity Reagents for Inactive Protein Kinasesdetermined (Figure 2C, bottom). Consistent with the in vitro
activity assays described above, kinases that have previously
been demonstrated to be able to adopt the DFG-out conforma-
tion (ABL, SRC, HCK, LCK, p38, EPHA3, and CSK) have a high
affinity for probe 4a, while other kinases (CLK1, PAK4, PAK5,
andMAP3K5) do not show a detectable level of binding (Table 1).
Because a large conformational change in the ATP-binding
pocket of kinases is required to accommodate inhibitor binding,
most type II inhibitors demonstrate slow binding kinetics. To
determine if 4a can be used to obtain type II inhibitor binding
kinetics, an assay that allows the measurement of the rate of
kinase-4a complex dissociation was developed. For this assay,
the catalytic domains of SRC, ABL, and p38 were incubated with
probe 4a under conditions in which >95% of the fluorescent
probe was bound. The reaction mixture was then diluted
30-fold into a solution containing a large excess of competitor
1a, to ensure that dissociated 4a cannot re-bind to the kinase.
By measuring the time-dependent loss in fluorescence, the
rate of dissociation of the SRC-4a, ABL-4a, and p38-4a
complexes were determined (Figure 2D). The data obtained
under these conditions fit well to a monoexponential decay
curve, with t1/2 for the SRC, ABL, and p38 complexes of 162,
220, and 72 min, respectively (Table 2). These data correlate
well with kinetic data that has been obtained for this class of
compounds and other type II inhibitors (Pargellis et al., 2002;
Seeliger et al., 2007, 2009; Sullivan et al., 2005).
We next investigated how mutations in the catalytic domains
of protein kinases affect the conformational dynamics of the
ATP-binding cleft. Specifically, probe 4a was used to study
how imatinib-resistance mutations in the P-loop affect the inter-
action of ABL kinasewith type II inhibitors (Table 2). The Kd of this
probe for two resistance mutants that are frequently observed in
patients with chronicmyelogenous leukemia that are undergoing
imatinib treatment, Y253H and E255V, was determined (Quintas-(D) Determination of the SRC-4a, ABL-4a, and p38-4a dissociative half-lives (t1/
which >95%of 4a (500 nM) is bound. The complexes were then diluted 30-fold into
of the kinase-probe complex. The rate of dissociation is measured by the decrea
then at 12 hr. Data was fit to a monoexponential decay curve. Assays were run i
Chemistry & Biology 17, 195Cardama et al., 2007). Consistent with inhibitors of this class not
making significant interactions with this flexible region of the
kinase, the Y253H mutant of ABL was found to have an identical
binding affinity for 4a as the wild-type enzyme. However, the
E255V mutant demonstrated a 4- to 5-fold weaker interaction.
The analogous mutants of SRC, F278H, and E280V were also
characterized. The less flexible nature of SRC’s P-loop is re-
flected in the identical kinetics and thermodynamics observed
for both mutants and wild-type. Finally, a gatekeeper mutant of
SRC, SRC T338I, was characterized. Similar to the underivatized
inhibitor, 4a has an equal affinity for wild-type and SRC T338I.
Despite this similarity in binding thermodynamics, the on
and off rates for 4a are two to three times faster for the gate-
keeper mutant.Generation of Affinity Matrices 14a and 15a
We determined the feasibility of converting compounds 1a and
3a into affinity pull-down reagents. These proteomic tools should
allow unbiased analyses of the kinases that are able to adopt the
DFG-out conformation in diverse cellular lysates. The 4-position
of ring A was modified with a flexible polyethylene glycol linker
that contains a primary amino group to allow selective immobili-
zation to a solid support (compounds 12a and 13a; Figure 3A).
Triazolopyridine 12d, which is an analog of control compound
2d, was also generated as a negative control for enrichment
studies. To determine whether linker attachment affects the
potency of this scaffold for kinases that adopt the DFG-out
conformation, in vitro activity assayswere performed (Figure 3C).
Gratifyingly, attachment of a flexible polyethylene glycol linker
does not alter the selectivity or potency of these inhibitors. Inhib-
itor-tethered resins containing 12a and 13a were generated by
the procedure shown in Figure 3B. In each coupling reaction,
the corresponding non-linkable analogs (1a, 3a, or 2d) were
included as controls. Addition of this internal standard allowed
the progress of the coupling reaction to be monitored by
observing the selective loss of the amine-containing compounds
12a, 13a, and 12d by HPLC (see Figures S1 and S2 available
online).2). The catalytic domains of these kinases were incubated under conditions in
a solution containing an excess of competitor 1a (5 mM) to prevent reformation
se in fluorescence over time. Fluorescence was read every 10 min for 8 hr, and
n triplicate.
–206, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 199
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Figure 3. Synthesis and Characterization of Immobilized type II Inhibitors
(A) Synthetic scheme for generating type II inhibitors that can be immobilized.
(B) Procedure for generating affinity matrices 14a (R1 = 12a), 14d (R1 = 12d), and 15a (R1 = 13a).
(C) IC50s of inhibitors 12a and 13a against a panel of kinases.
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Affinity Reagents for Inactive Protein KinasesAffinity Matrices 14a and 15a Enrich Kinases that Adopt
the DFG-Out Conformation
Amodel systemwas developed to determine the ability of affinity
matrices 14a and 15a to enrich kinases that are able to adopt the
DFG-out conformation. Optimal conditions for affinity capture,
resin washing, and protein elution were determined by adding
purified protein kinases to cellular lysates from E. coli (Figures200 Chemistry & Biology 17, 195–206, February 26, 2010 ª2010 Else4A and 4B). Because E. coli lack eukaryotic and eukaryotic-like
protein kinases, only exogenously added kinases should be re-
tained by the affinity matrix (Kannan et al., 2007). We first tested
the ability of affinity matrix 15a to enrich p38 kinase from lysates.
A majority of His6-p38 was retained by affinity matrix 15a after
2 hr of incubation as demonstrated by the lack of detectable
levels of His6-tagged kinase in the soluble fraction (Figure 4A).vier Ltd All rights reserved
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Figure 4. Characterization of Immobilized Type II Inhibitors 14a and 15a
(A) Enrichment of protein kinases from E. coli lysates with affinity resins 14a or 15a or control matrix 14d. Purified His6-p38 (4.6 mg), His6-ABL (5 mg), or HCK
(18 mg) were added to E. coli lysate (550–700 mg) and subjected to standard enrichment conditions with affinity matrix 15a or control matrix 14d. (Top) All fractions
were subjected to SDS-PAGE. ABL and p38 were detected with HisProbe-HRP (Pierce); SRC and HCK were detected with an antibody that specifically recog-
nizes SRC-family kinases that are dephosphorylated at Tyr416 in the activation loop [a-non-phospho-SRC(Y416)] (Cell Signaling). (Bottom) Elutions 1 and 2 from
the enrichment experiments described above were subjected to SDS-PAGE and silver stained.
(B) Enrichment of kinases that are sensitive to type II inhibitors in the presence of kinases that have not been characterized in the DFG-out conformation. His6-p38
(4 mg), His6-MAP3K5 (10 mg), and His6-PAK5 (10 mg) were added to E. coli lysate (500 mg) and subjected to standard enrichment conditions with affinity matrix
14a. The catalytic domain of SRC (4 mg), His6-MAP3K5 (4.5 mg), and His6-STK16 (4.5 mg) were added to E. coli lysate (600 mg) and subjected to standard enrich-
ment conditions with affinity matrix 14a. (Top) All fractions were subjected to SDS-PAGE and probedwith HisProbe-HRP or a-non-phospho-SRC(Y416). (Bottom)
Elutions 1 and 2 from the enrichment experiments described above were subjected to SDS-PAGE and silver stained. Note: Procedures for protein kinase expres-
sion and purification are in the Supplemental Experimental Procedures.
(C) Enrichment of endogenous kinases from HEK293 cell lysate. 600 mg of HEK293 lysate was subjected to standard enrichment conditions with affinity matrix
14a. All fractions were subjected to SDS-PAGE and probed with a-non-phospho-SRC(Y416) or a-LOK.
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Affinity Reagents for Inactive Protein KinasesFurthermore, no immobilized p38 was found to dissociate from
the resin after multiple washes. Repeated efforts to elute p38
from the affinity matrix with high concentrations of soluble,
ATP-competitive inhibitors were unsuccessful. This is most likely
due to the high affinity of the immobilized ligand for kinases that
adopt the DFG-out conformation and the slow rate of dissocia-
tion of these inhibitor-kinase complexes. However, a mild dena-
turant (0.5% SDS) allowed quantitative elution of this kinase.
Furthermore, these conditions appear to be selective for disrup-
tion of the kinase-inhibitor complex as demonstrated by the lack
of other proteins in the eluted fractions detected via silver stain-
ing. The same conditions were found to be effective for enriching
ABL and the SRC family kinase HCK (Figure 4A). As expected,
none of these kinases were retained by control matrix 14d. To
ensure that the affinity matrix selectively enriches kinases that
adopt the DFG-out conformation, p38was subjected to the stan-
dard affinity enrichment protocol in an E. coli protein lysate con-
taining the kinases PAK5 andMAP3K5 (Figure 4A). As expected,
only p38 was bound and retained by affinity matrix 14a. Further-
more, p38 was the only protein that could be detected in the
eluted fractions. Similar results were observed for SRC.
The ability of immobilized inhibitor 14a to enrich endogenous
protein kinases from mammalian lysates was tested. Western
blot analysis demonstrated that >90% of total SRC was retained
by the beads when 650 mg of HEK293 protein lysate was incu-
bated with affinity resin 14a (Figure 4C). SRC remained bound
to the affinity matrix during repeated washes and was eluted
with 0.5% SDS. Comparison of the proteins eluted from control
matrix 14d and affinity matrix 14a by SDS-PAGE followed by
silver staining demonstrated that several unique proteins were
enriched from HEK293 and HeLa cell lysates by immobilized
inhibitor 14a (Figure S3). However, a number of prominent bands
were present in the eluted fractions for both support-bound
ligands. These appear to be proteins that bind nonspecifically
to the matrix, as preincubation with control matrix 14d prior to
enrichment with 14a did not deplete a majority of these bands.
Mass spectrometric analysis of the proteins that were enriched
from HEK293 and HeLa cells is ongoing and will be reported
elsewhere. In parallel, a candidate approach for identifying
kinases that can adopt the DFG-out conformation was pursued.
Previous inhibitor screens have shown that the serine/threonine
kinase LOK is sensitive to several type II inhibitors (Angell et al.,
2008; Fabian et al., 2005; Karaman et al., 2008). However,
biochemical studies have not been performed to establish
whether LOK can adopt the DFG-out conformation. To deter-
mine whether endogenous LOK binds to the triazolopyridine
scaffold, HEK293 cell lysate was incubated with affinity matrix
14a. Immunoblot analysis of the bound and unbound fractions
with an a-LOK antibody demonstrated that a percentage of
this kinase was retained by the beads and selectively eluted.
The Catalytic Domain of LOK Behaves Similarly
to Other DFG-Out-Adopting Protein Kinases
To further characterize LOK, the His6-tagged catalytic domain of
this kinase was expressed and purified using a previously
described protocol (Fedorov et al., 2007). An in vitro activity
assay was developed for LOK and compounds 1a-c, 2a, and
3a were tested for their ability to inhibit this kinase. LOK was
found to be equally sensitive to inhibition by type II inhibitors202 Chemistry & Biology 17, 195–206, February 26, 2010 ª2010 Elseas other kinases that adopt the DFG-out conformation (Table
S1). Furthermore, resins 14a and 15a were able to enrich the
catalytic domain of LOK from E. coli lysate over other protein
kinases (Figure 5A). In addition, LOK was not retained by control
matrix 14d. To further confirm the affinity of LOK for the type II
inhibitor class, binding studies with probe 4a were performed.
Similar to other kinases that adopt the DFG-out conformation,
LOK has a high affinity for this fluorescently-labeled probe
(Kd = 12 nM; Figure 5B). Finally, the t1/2 for the LOK-4a complex
was determined (Figure 5C). Consistent with LOK demonstrating
slow binding kinetics for type II inhibitors, the t1/2 for this complex
was found to be 51min. Although the off rate for probe 4a is 3- to
4-fold faster than for SRC and ABL, the kinetics observed are
consistent with a conformational change being necessary for
ligand binding.
DISCUSSION
After it was discovered that the inhibitors imatinib and BIRB796
bind to the inactive forms of their kinase targets, there has been
widespread interest in the identification of small molecules that
selectively recognize alternate active site conformations (Liu
and Gray, 2006; Nagar et al., 2002; Okram et al., 2006; Schindler
et al., 2000). High selectivity can be achieved with inhibitors that
bind to inactive kinase conformations and the characteristically
long target residence times of these protein-small molecule
complexes may be beneficial from a therapeutic standpoint.
The DFG-out conformation is a specific inactive form that has
been successfully targeted by a number of type II inhibitors.
While it was once thought that only a few kinases are able to
adopt this conformation, recent studies have demonstrated
that it is accessible to many members of the human kinome
(Choi et al., 2009; Dar et al., 2008; DiMauro et al., 2006; Han
et al., 2009; Hodous et al., 2007; Mol et al., 2004; Schroeder
et al., 2009; Seeliger et al., 2009; Wan et al., 2004). However,
the sequence and structural determinants that allow a kinase
to adopt the DFG-out conformation are still not known and it is
not possible to predict which kinases will be sensitive to type II
inhibitors. To address this issue, our goalwas to identify a general
ligand for kinases that adopt the DFG-out conformation. We
have found that compounds based on the triazolopyridine scaf-
fold, which we have previously demonstrated through kinetic
and structural studies to bind the DFG-flipped forms of the
kinases ABL and SRC, potently inhibit a broad spectrum of
kinases that are sensitive to type II inhibitors. Furthermore, these
compounds do not inhibit other well-characterized kinases that
have not previously been observed in this specific inactive form.
A small panel of analogs based on the triazolopyridine scaffold
was generated to determine how substituents that occupy the
pocket created by the DFG motif flipping to a more solvent
exposed position affect kinase selectivity (Figure 1). As ex-
pected, a control compound that lacks a hydrophobic moiety
that occupies the DFG-out pocket and an amide group that
makes a set of characteristic hydrogen bonds with the backbone
amide of the DFG motif and a conserved glutamic acid in the
helix aC does not inhibit any of the DFG-out-adopting kinases.
Furthermore, an analog that contains a 3-trifluormethylbenza-
mide (1a), which is a general pharmacophore that occupies
the DFG-out pocket in many type II inhibitors, appears to bevier Ltd All rights reserved
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Figure 5. The Catalytic Domain of LOK Behaves Like a Kinase that Can Adopt the DFG-Out Conformation
(A) Enrichment of the catalytic domain of LOK from E. coli lysates with affinity resins 14a or 15a or control matrix 14d. (Top) Purified His6-LOK (4.5 mg) was added
to E. coli lysate (600 mg) and subjected to standard enrichment conditions with affinity matrix 15a. LOK was detected with HisProbe-HRP (Pierce). (Middle) Puri-
fied His6-LOK (4.5 mg) was added to E. coli lysate (600 mg) and subjected to standard enrichment conditions with control matrix 14d. LOK was detected with
HisProbe-HRP. (Bottom) Purified His6-LOK (4 mg), His6-CLK1 (10 mg), and His6-MAP3K5 (10 mg) were added to E. coli lysate (500 mg) and subjected to standard
enrichment conditions with affinity matrix 14a. All fractions were subjected to SDS-PAGE and kinases were detected with HisProbe-HRP (Pierce). (Bottom gels)
Elutions 1 and 2 from the enrichment experiments performed in the top and bottom panels above. Samples were subjected to SDS-PAGE and silver stained.
(B) Change in fluorescence observed with an increasing concentration of LOK in the presence of 5 nM of fluorescent probe 4a. Kd = 12 ± 1 nM. Value shown is the
average of three assays ± SEM.
(C) Determination of the LOK-4a complex dissociative half-life (t1/2). For LOK-4a, t1/2 = 51 min and koff = 2.3 3 10
5 s1. Assays were run in triplicate.
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Affinity Reagents for Inactive Protein Kinasesa nonselective ligand for kinases that have previously been char-
acterized to adopt the DFG-out conformation. Unexpectedly, re-
placing this pharmacophore with functional groups from more
selective type II inhibitors does not greatly enhance the selec-
tivity profile for compounds based on the triazolopyridine scaf-
fold. For example, compound 1b, which contains a 2-morphilino-
pyridyl group, is a nearly equipotent inhibitor of p38, ABL, SRC,
HCK, and CSK; however, inhibitors that display this moiety from
a 4-anilinoquinazoline scaffold are >500-fold selective for p38
over these kinases (Perera and Maly, 2008). Similarly, 1c, which
contains the functional groups present in the highly selective
BCR-ABL inhibitor nilotinib, is a fairly nonselective inhibitor of
DFG-out-adopting kinases. These data highlight that the ability
of some type II inhibitors to discriminate between closely related
kinases is most likely due to several unique protein-ligand inter-
actions rather than a single selectivity filter. Indeed, we have
demonstrated that a unique interaction between the P-loop of
ABL and imatinib makes a major contribution to the ability of
this compound to inhibit this kinase over closely related SRC
(Seeliger et al., 2009). Several recent reports that describe type
II inhibitors with limited selectivity profiles highlight that ligands
of this class have the potential to inhibit a much broader spec-Chemistry & Biology 17, 195trum of kinases than was previously appreciated (Angell et al.,
2008; Choi et al., 2009; Okram et al., 2006).
To gain a better understanding of how inhibitors based on the
triazolopyridine scaffold interact with protein kinases, we con-
verted compound 1a into a fluorescently-labeled ligand that
can be used in binding assays (Figure 2). The use of a binding
assay allows the affinity of this probe to be determined for
kinases in any activation state and facilitates the direct measure-
ment of ligand binding kinetics. As many type II inhibitors have
long residence times and slow on rates, determination of slow
binding kinetics with a general probe for the DFG-out conforma-
tion can be used to verify the ability of a kinase to adopt this
inactive form. In the presence of DFG-out-adopting kinases,
fluorescent probe 4a demonstrated a concentration-dependent
increase in fluorescence. An assay was developed to measure
the residence time of this probe when bound to p38, SRC, and
ABL. The slow binding kinetics demonstrated by this probe are
similar to those observed for other type II inhibitors of these
kinases (Pargellis et al., 2002; Seeliger et al., 2007, 2009; Sullivan
et al., 2005). This assay was also used to study how drug-resis-
tance mutations affect the interactions of kinases with type II
inhibitors. A mutation to the flexible P-loop region of ABL,–206, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 203
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Affinity Reagents for Inactive Protein KinasesE255V, was found to reduce the affinity of this kinase for the
probe. Interestingly, the observed loss in affinity is due to
a slower on rate rather than a slower rate of dissociation. None
of the analogous P-loop mutations in SRC were found to affect
the interaction of this kinase with type II inhibitors, which is
consistent with this region not interacting with inhibitors. Finally,
mutation of the gatekeeper residue of SRC to a bulkier residue
was found to affect both the on and off rates of ligand binding.
This result is consistent with recent findings that mutation of
the gatekeeper residue in ABL causes increased conformational
disturbances in a specific catalytic domain region of this kinase
(Iacob et al., 2009).
While structural studies and kinetic assays can be used to
determine if a kinase can adopt the DFG-out conformation, these
methods can only be performed on purified proteins. Because it
is difficult to know whether the conformational preferences of
a recombinantly expressed purified kinase are representative
of those in a cell, probes that allow interrogation of endogenous
kinases are highly desirable. For this reason, we developed
a support-bound affinity matrix based on inhibitor 1a that allows
an unbiased sampling of mammalian lysates. We first verified
that our affinity matrix was capable of enriching purified kinases
that are known to be sensitive to type II inhibitors from complex
mixtures (Figure 4). Indeed, affinity matrices 14a and 15a selec-
tively enriched SRC, HCK, and p38 from an E. coli lysate but not
kinases that are insensitive to type II inhibitors. Importantly,
control matrix 14d, which does not contain a pharmacophore
that occupies the DFG-out pocket, does not enrich any of the
kinases tested. We next tested this reagent in mammalian cell
lysates. First, it was verified that affinity matrix 14a was able
to enrich endogenous SRC from HEK293 cells. Analysis of the
proteins that were selectively enrichedwith affinity resin 14a over
control matrix 14d fromHeLa andHEK293 lysates demonstrated
that there are several unique proteins. Mass spectrometric
identification of these proteins is currently being performed.
A candidate approach using western blot analysis was adop-
ted to discover novel DFG-out-adopting kinases. We found that
the STE20 kinase LOK could be selectively enriched from
HEK293 lysates with affinity matrix 14a. Furthermore, the puri-
fied catalytic domain could be enriched from E. coli lysates
and was sensitive (IC50 < 20 nM) to type II inhibitors 1a-1c, 2a,
and 3a in activity assays (Table S1). Finally, LOK demonstrated
similarly slow binding kinetics with type II inhibitors such as
ABL, SRC, and p38. Besides p38 and RAF, no other serine/
threonine kinases have been characterized in the DFG-out con-
formation. Furthermore, no members of the STE20 kinase family
have been found to be sensitive to type II inhibitors. Indeed,
MAP3K5, PAK4, and PAK5, which are STE20 kinases and
much more closely related to LOK than SRC or ABL, were not
sensitive to any of the affinity reagents that we have developed.
LOK is also of interest because it contains a residue with a bulky
side chain (isoleucine) at the gatekeeper position. To date, a vast
majority of the kinases that have been characterized to adopt the
DFG-out conformation (except Tie-2, PYK2, and c-MET) contain
either a threonine or valine at this position. However, the pres-
ence of a larger gatekeeper residue does not preclude a kinase
from adopting this form. While conversion of the threonione
gatekeeper of ABL to an isoleucine results in this kinase being
resistant to the type II inhibitors imatinib and nilotinib, several204 Chemistry & Biology 17, 195–206, February 26, 2010 ª2010 Elsetype II inhibitors that are extremely potent against this mutant
have been described (Huang et al., 2009; O’Hare et al., 2009;
Seeliger et al., 2009). Expanding the number and diversity of
kinases that are known to stably adopt the DFG-out conforma-
tion will allow the identification of the sequence determinants
that allow this transition.
SIGNIFICANCE
A number of type II inhibitors have been developed that
target an inactive form of the ATP-binding site of kinases
called the DFG-out conformation. Once thought to be ener-
getically accessible to only a few kinases, the DFG-out
conformation has been characterized with an increasing
number of enzymes from this family. However, it is still not
possible to predict which members of the kinome are able
to stably adopt this inactive conformation. In addition, the
structural and sequence determinants of this transition
remain poorly understood. Here, we have identified a scaf-
fold that appears to be a general pharmacophore for the
DFG-out conformation. Derivatives of this scaffold are
potent inhibitors of kinases that have previously been char-
acterized to be sensitive to type II inhibitors. Furthermore,
fluorophore-conjugated versions of these molecules allow
the determination of the thermodynamics and kinetics of
ligand binding to any activation state of the kinase catalytic
domain. In addition, immobilized analogs of the general
scaffold were found to be effective reagents for enriching
DFG-out-adopting kinases from complex protein mixtures.
Affinity reagents 14a and 15a were used to demonstrate
that the STE20 kinase LOK behaves like other DFG-out-
adopting kinases. LOK is distantly related to other members
of the kinase family that have been characterized in theDFG-
out conformation. Use of these reagents to discover the full
complement of kinases that are able to stably adopt the
DFG-out conformation will allow a greater understanding
of the thermodynamics and kinetics of the catalytic domains
of this enzyme family.
EXPERIMENTAL PROCEDURES
Synthetic Methods
Detailed synthetic procedures are in the Supplemental Experimental Proce-
dures.
Affinity Measurements with Probe 4a
Purified kinase (initial concentration = 250 nM, 2-fold serial dilution down to
0.2 nM) was incubated with 5 or 10 nM 4a in 120 ml of buffer containing
20 mM Tris (pH 7.5), 2% DMSO, 100 mM KCl, 10% glycerol, 1 mM DTT,
0.05% Pluronic F-68, and 1 mM MgCl2. Fluorescence was read after 30 min
of incubation at room temperature (excitation = 485 nm; emission = 535 nm).
The Kd was determined by fitting the data to non-linear regression analysis
(one site total binding) with Prism GraphPad software.
Determination of t1/2 with Probe 4a
Purified kinase (700 nM) was incubatedwith 4a (500 nM) in 120 ml of buffer con-
taining 20mMTris (pH 7.5), 2%DMSO, 100mMKCl, 10%glycerol, 1 mMDTT,
0.05% Pluronic F-68, and 1 mM MgCl2. After 4 hr, the mixture was diluted
30-fold ([4a] = 17 nM) into the same buffer containing 5 mMof 1a. Fluorescence
was read every 10 min for 8 hr, and then at 12 hr (excitation = 485 nm; emis-
sion = 535 nm). Off rates (koff) and dissociative half-lives (t1/2) were determinedvier Ltd All rights reserved
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GraphPad software.
Generation of Affinity Matrix 14a
A modification of a previously published procedure was used (Wissing et al.,
2007). 1.5 ml of ECH Sepharose resin was washed with 10 bed volumes of
H2O (pH 4.5; 0.5 M NaCl) and 1:1 DMF/EtOH. 3 ml of 0.75 mM 12a and
0.46 mM 1a in 1:1 DMF/EtOH was added to the resin followed by 30 ml of
DIEA and 450 ml of 1 M EDCI in 1:1 DMF/EtOH. The reaction mixture was
rotated for 48 hr and monitored by analytical HPLC (Figures S2 and S3). After
48 hr, the reaction mixture was drained and washed with 2 bed volumes of 1:1
DMF/EtOH. The resin was then incubated with 56 ml ethanolamine, 933 ml of
20 mM acetic acid, and 450 ml of EDCI in 1:1 DMF/EtOH for 12 hr, followed
by washing with 6 bed volumes of 1:1 DMF/EtOH (33), 6 bed volumes of
0.5 M NaCl (23), and 10 bed volumes of 20% EtOH. The resin was stored at
4C in 20% EtOH until further use. Affinity matrices 14d and 15a were gener-
ated by the same method.
General Method for Affinity Enrichment from E. coli Lysate
50 ml of affinity matrix 14a, 14d, or 15a was washed with 8 bed volumes of
a buffer containing 50 mM HEPES (pH 7.5), 0.5% Triton X-100, 1 mM EDTA,
1 mM EGTA, and 100 mM NaCl. Purified kinase (4–18 mg) and E. coli lysate
protein (500–800 mg) in 250 ml of binding buffer [50 mM HEPES (pH 7.5),
0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA, 20 mM MgCl2, 1 M NaCl, and
100 mg/ml PMSF] was added to the resin and incubated for 2 hr at 4C. The
resin was then drained, incubated with 8 bed volumes of binding buffer for
30 min at 4C, and drained again (4 washes). After the final wash, 1.5 bed
volumes of 0.5% SDS in binding buffer was added to the resin and incubated
for 10 min at room temperature. The eluted protein was collected and this
process was repeated. All collected fractions were subjected to SDS-PAGE,
transferred to nitrocellulose, and subjected to western blot analysis. Eluted
fractions were also subjected to SDS-PAGE and stained with Silver Stain
Xpress (Invitrogen).
GeneralMethod for Affinity Enrichment fromMammalianCell Lysate
50–150 ml of affinity matrix 14a, 14d, or 15awas washed with 8 bed volumes of
a buffer containing 50 mM HEPES (pH 7.5), 0.5% Triton X-100, 1 mM EDTA,
1 mM EGTA, and 100 mM NaCl. HEK293 or HeLa lysate proteins (0.6–8 mg)
in 0.25–1.0 ml of buffer containing 50 mM HEPES (pH 7.5), 0.5% Triton X-100,
1mMEDTA, 1mMEGTA, 2.5 mM sodium orthovanadate, 1 mMPMSF, Roche
protease inhibitor cocktail, and 20mMMgCl2 was added to the resin and incu-
bated for 2 hr at 4C. The resin was then drained, incubated with 8 bed
volumes of binding buffer for 30min at 4C, and drained again (4 washes). After
the final wash, 3–4 bed volumes of 0.5% SDS in binding buffer was added to
the resin and incubated for 10min at room temperature. The eluted protein was
collected and this process was repeated. All collected fractions were lyophi-
lized, subjected to SDS-PAGE, transferred to nitrocellulose, and subjected
to western blot analysis with an a-non-phospho-SRC(Y416) or a-LOK anti-
body. Eluted fractions were subjected to SDS-PAGE and stained with Silver
Stain Xpress.SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, three
figures, and one table and can be found with this article online at doi:10.1016/
j.chembiol.2010.01.008.
ACKNOWLEDGMENTS
We thank J. Kuriyan (University of California, Berkeley) and M. Seeliger (State
University of New York, Stony Brook) for providing expression plasmids for
ABL (cat), SRC (cat), HCK (cat), HCK (3D), LCK (3D), SRC (3D), and ABL
(3D). We thank S. Knapp (Structural Genomics Consortium) for providing
expression plasmids for CLK1, STK16, EPHA3, PAK4, PAK5, MAP3K5, and
LOK. This work was supported by the National Institute of General Medical
Science (R01GM086858 to D.J.M.).Chemistry & Biology 17, 195Received: December 1, 2009
Revised: January 18, 2010
Accepted: January 20, 2010
Published: February 25, 2010
REFERENCES
Angell, R.M., Angell, T.D., Bamborough, P., Bamford, M.J., Chung, C.W.,
Cockerill, S.G., Flack, S.S., Jones, K.L., Laine, D.I., Longstaff, T., et al.
(2008). Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding
modes. Bioorg. Med. Chem. Lett. 18, 4433–4437.
Choi, Y., Syeda, F., Walker, J.R., Finerty, P.J., Jr., Cuerrier, D., Wojciechowski,
A., Liu, Q., Dhe-Paganon, S., and Gray, N.S. (2009). Discovery and structural
analysis of Eph receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett.
19, 4467–4470.
Cohen, P. (2000). The regulation of protein function by multisite phosphoryla-
tion—a 25 year update. Trends Biochem. Sci. 25, 596–601.
Cohen, P. (2002). Protein kinases—the major drug targets of the twenty-first
century? Nat. Rev. Drug Discov. 1, 309–315.
Cumming, J.G., McKenzie, C.L., Bowden, S.G., Campbell, D., Masters, D.J.,
Breed, J., and Jewsbury, P.J. (2004). Novel, potent and selective anilinoquina-
zoline and anilinopyrimidine inhibitors of p38MAP kinase. Bioorg. Med. Chem.
Lett. 14, 5389–5394.
Dar, A.C., Lopez, M.S., and Shokat, K.M. (2008). Small molecule recognition of
c-Src via the Imatinib-binding conformation. Chem. Biol. 15, 1015–1022.
DiMauro, E.F., Newcomb, J., Nunes, J.J., Bemis, J.E., Boucher, C., Buchanan,
J.L., Buckner, W.H., Cee, V.J., Chai, L., Deak, H.L., et al. (2006). Discovery of
aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis,
SAR, and in vivo anti-inflammatory activity. J. Med. Chem. 49, 5671–5686.
Engh, R.A., and Bossemeyer, D. (2001). The protein kinase activity modulation
sites: mechanisms for cellular regulation - targets for therapeutic intervention.
Adv. Enzyme Regul. 41, 121–149.
Fabian, M.A., Biggs, W.H., III, Treiber, D.K., Atteridge, C.E., Azimioara, M.D.,
Benedetti, M.G., Carter, T.A., Ciceri, P., Edeen, P.T., Floyd, M., et al. (2005).
A small molecule-kinase interaction map for clinical kinase inhibitors. Nat.
Biotechnol. 23, 329–336.
Fedorov, O., Marsden, B., Pogacic, V., Rellos, P., Muller, S., Bullock, A.N.,
Schwaller, J., Sundstrom, M., and Knapp, S. (2007). A systematic interaction
map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad.
Sci. USA 104, 20523–20528.
Han, S., Mistry, A., Chang, J.S., Cunningham, D., Griffor, M., Bonnette, P.C.,
Wang, H., Chrunyk, B.A., Aspnes, G.E., Walker, D.P., et al. (2009). Structural
characterization of proline-rich tyrosine kinase 2 (PYK2) reveals a unique
(DFG-out) conformation and enables inhibitor design. J. Biol. Chem. 284,
13193–13201.
Hanks, S.K., and Hunter, T. (1995). Protein kinases 6. The eukaryotic protein
kinase superfamily: kinase (catalytic) domain structure and classification.
FASEB J. 9, 576–596.
Hodous, B.L., Geuns-Meyer, S.D., Hughes, P.E., Albrecht, B.K., Bellon, S.,
Bready, J., Caenepeel, S., Cee, V.J., Chaffee, S.C., Coxon, A., et al. (2007).
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2
kinase inhibitor. J. Med. Chem. 50, 611–626.
Huang, W.S., Zhu, X., Wang, Y., Azam, M., Wen, D., Sundaramoorthi, R.,
Thomas, R.M., Liu, S., Banda, G., Lentini, S.P., et al. (2009). 9-(Arenethenyl)-
purines as dual Src/Abl kinase inhibitors targeting the inactive conformation:
design, synthesis, and biological evaluation. J. Med. Chem. 52, 4743–4756.
Huse, M., and Kuriyan, J. (2002). The conformational plasticity of protein
kinases. Cell 109, 275–282.
Iacob, R.E., Pene-Dumitrescu, T., Zhang, J., Gray, N.S., Smithgall, T.E., and
Engen, J.R. (2009). Conformational disturbance in Abl kinase upon mutation
and deregulation. Proc. Natl. Acad. Sci. USA 106, 1386–1391.
Jacobs, M.D., Caron, P.R., and Hare, B.J. (2008). Classifying protein kinase
structures guides use of ligand-selectivity profiles to predict inactive confor-
mations: structure of lck/imatinib complex. Proteins 70, 1451–1460.–206, February 26, 2010 ª2010 Elsevier Ltd All rights reserved 205
Chemistry & Biology
Affinity Reagents for Inactive Protein KinasesJeffrey, P.D., Russo, A.A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J., and
Pavletich, N.P. (1995). Mechanism of CDK activation revealed by the structure
of a cyclinA-CDK2 complex. Nature 376, 313–320.
Kannan, N., Taylor, S.S., Zhai, Y., Venter, J.C., and Manning, G. (2007). Struc-
tural and functional diversity of the microbial kinome. PLoS Biol. 5, e17.
Karaman,M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Camp-
bell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., et al. (2008). A quan-
titative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127–132.
Kornev, A.P., Haste, N.M., Taylor, S.S., and Eyck, L.F. (2006). Surface compar-
ison of active and inactive protein kinases identifies a conserved activation
mechanism. Proc. Natl. Acad. Sci. USA 103, 17783–17788.
Liu, Y., and Gray, N.S. (2006). Rational design of inhibitors that bind to inactive
kinase conformations. Nat. Chem. Biol. 2, 358–364.
Manning, G.,Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002).
The protein kinase complement of the human genome. Science 298, 1912–
1934.
Mol, C.D., Dougan, D.R., Schneider, T.R., Skene, R.J., Kraus, M.L., Scheibe,
D.N., Snell, G.P., Zou, H., Sang, B.C., andWilson, K.P. (2004). Structural basis
for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol.
Chem. 279, 31655–31663.
Nagar, B., Bornmann, W.G., Pellicena, P., Schindler, T., Veach, D.R., Miller,
W.T., Clarkson, B., and Kuriyan, J. (2002). Crystal structures of the kinase
domain of c-Abl in complex with the small molecule inhibitors PD173955
and imatinib (STI-571). Cancer Res. 62, 4236–4243.
O’Hare, T., Shakespeare, W.C., Zhu, X., Eide, C.A., Rivera, V.M., Wang, F.,
Adrian, L.T., Zhou, T., Huang, W.S., Xu, Q., et al. (2009). AP24534, a pan-
BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I
mutant and overcomes mutation-based resistance. Cancer Cell 16, 401–412.
Okram, B., Nagle, A., Adrian, F.J., Lee, C., Ren, P., Wang, X., Sim, T., Xie, Y.,
Wang, X., Xia, G., et al. (2006). A general strategy for creating ‘‘inactive-confor-
mation’’ abl inhibitors. Chem. Biol. 13, 779–786.
Pargellis, C., Tong, L., Churchill, L., Cirillo, P.F., Gilmore, T., Graham, A.G.,
Grob, P.M., Hickey, E.R., Moss, N., Pav, S., et al. (2002). Inhibition of p38
MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9,
268–272.
Pellicena, P., and Kuriyan, J. (2006). Protein-protein interactions in the allo-
steric regulation of protein kinases. Curr. Opin. Struct. Biol. 16, 702–709.
Perera, B.G., and Maly, D.J. (2008). Design, synthesis and characterization of
‘‘clickable’’ 4-anilinoquinazoline kinase inhibitors. Mol. Biosyst. 4, 542–550.
Quintas-Cardama, A., Kantarjian, H., and Cortes, J. (2007). Flying under
the radar: the new wave of BCR-ABL inhibitors. Nat. Rev. Drug Discov. 6,
834–848.
Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kur-
iyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine
kinase. Science 289, 1938–1942.206 Chemistry & Biology 17, 195–206, February 26, 2010 ª2010 ElseSchroeder, G.M., An, Y.M., Cai, Z.W., Chen, X.T., Clark, C., Cornelius, L.A.M.,
Dai, J., Gullo-Brown, J., Gupta, A., Henley, B., et al. (2009). Discovery of
N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluoro-
phenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective
and orally efficacious inhibitor of the Met kinase superfamily. J. Med. Chem.
52, 1251–1254.
Seeliger, M.A., Nagar, B., Frank, F., Cao, X., Henderson, M.N., and Kuriyan, J.
(2007). c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit
conformation and a distributed thermodynamic penalty. Structure 15,
299–311.
Seeliger, M.A., Ranjitkar, P., Kasap, C., Shan, Y., Shaw, D.E., Shah, N.P., Kur-
iyan, J., and Maly, D.J. (2009). Equally potent inhibition of c-Src and Abl by
compounds that recognize inactive kinase conformations. Cancer Res. 69,
2384–2392.
Simard, J.R., Getlik, M., Gru¨tter, C., Pawar, V., Wulfert, S., Rabiller, M., and
Rauh, D. (2009a). Development of a fluorescent-tagged kinase assay system
for the detection and characterization of allosteric kinase inhibitors. J. Am.
Chem. Soc. 131, 13286–13296.
Simard, J.R., Kluter, S., Gru¨tter, C., Getlik, M., Rabiller, M., Rode, H.B., and
Rauh, D. (2009b). A new screening assay for allosteric inhibitors of cSrc.
Nat. Chem. Biol. 5, 394–396.
Sullivan, J.E., Holdgate, G.A., Campbell, D., Timms, D., Gerhardt, S., Breed, J.,
Breeze, A.L., Bermingham, A., Pauptit, R.A., Norman, R.A., et al. (2005).
Prevention of MKK6-dependent activation by binding to p38alpha MAP
kinase. Biochemistry 44, 16475–16490.
Taylor, S.S., Bubis, J., Toner-Webb, J., Saraswat, L.D., First, E.A., Buechler,
J.A., Knighton, D.R., and Sowadski, J. (1988). CAMP-dependent protein
kinase: prototype for a family of enzymes. FASEB J. 2, 2677–2685.
Wan, P.T., Garnett, M.J., Roe, S.M., Lee, S., Niculescu-Duvaz, D., Good, V.M.,
Jones, C.M., Marshall, C.J., Springer, C.J., Barford, D., and Marais, R. (2004).
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic
mutations of B-RAF. Cell 116, 855–867.
Weisberg, E., Manley, P.W., Breitenstein, W., Bruggen, J., Cowan-Jacob,
S.W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al.
(2005). Characterization of AMN107, a selective inhibitor of native and mutant
Bcr-Abl. Cancer Cell 7, 129–141.
Wissing, J., Jansch, L., Nimtz, M., Dieterich, G., Hornberger, R., Keri, G., Weh-
land, J., and Daub, H. (2007). Proteomics analysis of protein kinases by target
class-selective prefractionation and tandem mass spectrometry. Mol. Cell.
Proteomics 6, 537–547.
Wong, L., Jennings, P.A., and Adams, J.A. (2004). Communication pathways
between the nucleotide pocket and distal regulatory sites in protein kinases.
Acc. Chem. Res. 37, 304–311.vier Ltd All rights reserved
